CHARACTERISTICS, RESOURCES UTILIZATION AND SAFETY PROFILE OF PATIENTS WITH ACUTE PAIN- A EUROPEAN REAL WORLD EVIDENCE STUDY
Author(s)
Katz P1, Pegoraro V2, Heiman F2, Liedgens H1
1Grünenthal GmbH, Aachen, Germany, 2IMS Health Information Solutions Italy S.r.l., Milan, Italy
OBJECTIVES: To identify characteristics, resources utilization and safety profile of patients with acute pain prescribed with Lidocaine 5% plasters, Pregabalin, Gabapentin, Amitriptyline, Duloxetine. METHODS: Retrospective analysis on Real World Data from IMS Health Longitudinal Patient Database in Italy, Germany, UK, Spain, Belgium. All patients with at least one prescription of the drugs of interest during 2014 were selected. Patients with a diagnosis not compatible with pain, patients previously treated with the drugs of interest and patients treated with more than one drug of interest were excluded. For each patient, demographic and clinical characteristics, co-prescriptions, examinations, specialist visits and hospitalizations were collected. Adverse Drug Reactions (ADRs) as described in the leaflet were searched to evaluate patients’ safety profile. Multivariate logistic models were implemented to understand whether there was an association between treatments and ADRs occurrence. RESULTS: Patients were selected from Italy (11,287), Germany (5,604), UK (70,515), Spain (10,700 ) and Belgium (2,513). In all countries, patients treated with Lidocaine 5% plasters were older than those in the other groups and more women were treated with Lidocaine 5% plasters, Amitriptyline and Duloxetine than with Pregabalin and Gabapentin. Lidocaine 5% plasters patients had fewer co-medication prescriptions, but no relevant differences were found in the number of specialist visits, examinations and hospitalizations. Compared to all other treatments, significantly less Lidocaine 5% plasters patients experienced at least one ADR in all countries, with odds ratios in favor of Lidocaine 5% plasters, ranging from 3.41 (p=0.036) to 52.33 (p<0.001). CONCLUSIONS: Although Lidocaine 5% plasters treated patients were older, their resources utilization profile was comparable to those of the other treatments, but their likelihood of experiencing ADRs was significantly lower. These Real World Data confirm the findings from clinical and observational studies with the Lidocaine 5% plaster.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSY20
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Systemic Disorders/Conditions